# advanced melanoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-melanoma

> 6 upcoming FDA catalysts in advanced melanoma: brenetafusp (IMCR) on Oct 2027 to Jan 2028 (topline data readout); brenetafusp (IMCR) on October 2027 (primary completion); KIMMTRAK (tebentafusp, IMCR) on March 2028 (primary completion); KIMMTRAK (tebentafusp, IMCR) on Mar to Jun 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 21, 2025 | [Vusolimogene oderparepvec NDA/BLA acceptance](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed | "Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for patients with advanced melanoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925005291/tm254066d1_ex99-1.htm)) |
| July 21, 2025 | [Vusolimogene oderparepvec complete response letter (CRL)](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed, complete response letter | "COMPLETE RESPONSE letter dated 07/21/2025 for BL 125827 to Replimune, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA125827_20250721.pdf%22)) |
| July 22, 2025 | [Replimune Group, Inc. complete response letter (CRL)](https://sec-api.dev/companies/repl/catalysts) | REPL | advanced melanoma | completed, complete response letter | "The complaint, captioned Jboor v. Replimune Group, Inc. et al., Case No. 1:25-cv-12085-JEK, was filed shortly after the Company announced it received a complete response letter from the FDA for its RP1 BLA for the treatment of advanced melanoma on July 22, 2025 and the subsequent decline in the trading price of the Company's common stock." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1737953/000162828026067722/repl-20260930.htm)) |
| April 10, 2026 | [Opdivo® (nivolumab) PDUFA date](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "The PDUFA date set by the FDA is April 10, 2026 based on a Class II resubmission timeline." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1737953/000110465925100605/tm2529069d1_8k.htm)) |
| April 10, 2026 | [Opdivo® (nivolumab) complete response letter (CRL)](https://sec-api.dev/pdufa/nivolumab) | REPL | advanced melanoma | completed, complete response letter | "On April 10, 2026 the Company received a CRL from the FDA for the BLA for RP1 in combination with nivolumab for the treatment of advanced melanoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1737953/000162828026045886/repl-20260331.htm)) |
| April 27, 2026 | [Botvymo® (botensilimab) primary completion](https://sec-api.dev/pdufa/botensilimab) | AGEN | Advanced Melanoma | withdrawn | "NCT05529316 (A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor Agenus Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05529316)) |
| June 29, 2026 | [Vusolimogene oderparepvec NDA/BLA acceptance](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | advanced melanoma | completed | "The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465926078511/tm2619129d1_ex99-1.htm)) |
| Oct 2027 to Jan 2028 | [Brenetafusp topline data readout](https://sec-api.dev/pdufa/brenetafusp) | IMCR | Advanced Melanoma | scheduled | "NCT06112314 (IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-16 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112314)) |
| October 2027 | [Brenetafusp primary completion](https://sec-api.dev/pdufa/brenetafusp) | IMCR | Advanced Melanoma | scheduled | "NCT06112314 (IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-16 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06112314)) |
| March 2028 | [KIMMTRAK (tebentafusp) primary completion](https://sec-api.dev/pdufa/tebentafusp) | IMCR | Advanced Melanoma | scheduled | "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549297)) |
| Mar to Jun 2028 | [KIMMTRAK (tebentafusp) topline data readout](https://sec-api.dev/pdufa/tebentafusp) | IMCR | Advanced Melanoma | scheduled | "NCT05549297 (Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Immunocore Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05549297)) |
| Sep to Dec 2030 | [Vusolimogene oderparepvec topline data readout](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | Advanced Melanoma | scheduled | "NCT06264180 (VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-30 (ESTIMATED); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06264180)) |
| September 2030 | [Vusolimogene oderparepvec primary completion](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) | REPL | Advanced Melanoma | scheduled | "NCT06264180 (VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-30 (ESTIMATED); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06264180)) |

## Drugs

- [Vusolimogene oderparepvec](https://sec-api.dev/pdufa/vusolimogene-oderparepvec) (REPL)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)
- [Brenetafusp](https://sec-api.dev/pdufa/brenetafusp) (IMCR)
- [KIMMTRAK (tebentafusp)](https://sec-api.dev/pdufa/tebentafusp) (IMCR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-melanoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "advanced melanoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-melanoma

```bibtex
@misc{secapidev_indications_advanced_melanoma_20261116,
  title        = {advanced melanoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-melanoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_melanoma_20261116","title":"advanced melanoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-melanoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
